Related Experiment Video
Updated: Sep 30, 2025

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
Muti-omics integration analysis revealed molecular network alterations in human nonfunctional pituitary
Siqi Wen1,2,3, Chunling Li4, Xianquan Zhan1,2,5
1Shandong Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, 440 Jiyan Road, Jinan, Shandong 250117 People's Republic of China.
Abstract:
Nonfuctional pituitary neuroendocrine tumor (NF-PitNET) is highly heterogeneous and generally considered a common intracranial tumor. A series of molecules are involved in NF-PitNET pathogenesis that alter in multiple levels of genome, transcriptome, proteome, and metabolome, and those molecules mutually interact to form dynamically associated molecular-network systems. This article reviewed signaling pathway alterations in NF-PitNET based on the analyses of the genome, transcriptome, proteome, and metabolome, and emphasized signaling pathway network alterations based on the integrative omics, including calcium signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway, PI3K/AKT signaling pathway, MAPK (mitogen-activated protein kinase) signaling pathway, oxidative stress response, mitochondrial dysfunction, and cell cycle dysregulation, and those signaling pathway networks are important for NF-PitNET formation and progression. Especially, this review article emphasized the altered signaling pathways and their key molecules related to NF-PitNET invasiveness and aggressiveness that are challenging clinical problems. Furthermore, the currently used medication and potential therapeutic agents that target these important signaling pathway networks are also summarized. These signaling pathway network changes offer important resources for insights into molecular mechanisms, discovery of effective biomarkers, and therapeutic targets for patient stratification, predictive diagnosis, prognostic assessment, and targeted therapy of NF-PitNET.
Insights
Nonfunctional pituitary neuroendocrine tumors (NF-PitNETs) involve complex molecular networks. Understanding these altered signaling pathways offers new therapeutic targets for aggressive tumors.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Nonfunctional pituitary neuroendocrine tumors (NF-PitNETs) are common intracranial tumors with significant heterogeneity.
- NF-PitNET pathogenesis involves alterations across genomic, transcriptomic, proteomic, and metabolomic levels, forming complex molecular networks.
Purpose of the Study:
- To review signaling pathway alterations in NF-PitNETs using integrative omics data.
- To emphasize pathways linked to NF-PitNET invasiveness and aggressiveness.
- To summarize current and potential therapeutic agents targeting these pathways.
Main Methods:
- Integrative omics analyses (genome, transcriptome, proteome, metabolome).
- Review of literature on signaling pathway alterations in NF-PitNETs.
- Focus on pathways including calcium, cGMP-PKG, mTOR, PI3K/AKT, and MAPK signaling.
Main Results:
- Identified key signaling pathway networks crucial for NF-PitNET formation and progression.
- Highlighted altered pathways and molecules associated with tumor invasiveness and aggressiveness.
- Summarized targeted therapies and potential agents for NF-PitNET treatment.
Conclusions:
- Signaling pathway network alterations are central to NF-PitNET development and progression.
- Understanding these networks provides insights into molecular mechanisms and identifies therapeutic targets.
- This knowledge aids in biomarker discovery, patient stratification, and targeted NF-PitNET therapy.
More Related Videos
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024